Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen M Ansell

Showing results (1-10 of 555) with videos related to

Pageof 56
Sort By:
American Journal of Hematology|September 17, 2011
Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and managementStephen M Ansell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2016
Nivolumab in the Treatment of Hodgkin LymphomaStephen M Ansell
Hematology. American Society of Hematology. Education Program|December 4, 2020
Fundamentals of immunology for understanding immunotherapy for lymphomaStephen M Ansell
Hematology/Oncology Clinics of North America|November 30, 2013
Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse)Stephen M Ansell
Blood|March 21, 2015
DNA methylation in lymphoma: an opportunity?Stephen M Ansell
The Lancet. Haematology|January 8, 2019
Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphomaStephen M Ansell
Blood Advances|November 24, 2020
Fundamentals of immunology for understanding immunotherapy for lymphomaStephen M Ansell
Journal of Oncology Practice|February 13, 2016
Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?Stephen M Ansell
American Journal of Hematology|April 11, 2018
Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and managementStephen M Ansell
Hemasphere|November 15, 2019
Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin LymphomaStephen M Ansell
Pageof 56

Showing results (1-10 of 555) with videos related to

Sort By:
Pageof 56
American Journal of Hematology|September 17, 2011
Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and managementStephen M Ansell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2016
Nivolumab in the Treatment of Hodgkin LymphomaStephen M Ansell
Hematology. American Society of Hematology. Education Program|December 4, 2020
Fundamentals of immunology for understanding immunotherapy for lymphomaStephen M Ansell
Hematology/Oncology Clinics of North America|November 30, 2013
Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse)Stephen M Ansell
Blood|March 21, 2015
DNA methylation in lymphoma: an opportunity?Stephen M Ansell
The Lancet. Haematology|January 8, 2019
Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphomaStephen M Ansell
Blood Advances|November 24, 2020
Fundamentals of immunology for understanding immunotherapy for lymphomaStephen M Ansell
Journal of Oncology Practice|February 13, 2016
Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?Stephen M Ansell
American Journal of Hematology|April 11, 2018
Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and managementStephen M Ansell
Hemasphere|November 15, 2019
Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin LymphomaStephen M Ansell
Pageof 56